Fortimedix Surgical Strengthens U.S. Commercial Team with Appointment of David Castiglioni as Vice President of Sales in the United States


NUTH, The Netherlands and SAN DIEGO, May 24, 2017 (GLOBE NEWSWIRE) -- Fortimedix Surgical today announced the appointment of David Castiglioni as Vice President of Sales in the United States. Under Mr. Castiglioni’s leadership, the Fortimedix Surgical commercial team will further expand sales of the symphonX™ Surgical Platform, the company’s flagship product and the world’s lowest profile single-port surgery solution.

“Fortimedix Surgical is well-positioned to achieve its strategic goals for near- and long-term growth with the appointment of Mr. Castiglioni,” said Wout Bijker, CEO. “David brings a wealth of knowledge within the medical device space, particularly around market introductions of disruptive technologies, and we will benefit greatly from his leadership and expertise.”

Mr. Castiglioni has over 18 years of medical device sales and marketing experience, including senior leadership roles at Intuitive Surgical and Abbott Vascular, where he built and led cohesive sales teams to success within a variety of medical device markets in the United States. He joins Fortimedix Surgical from MiMedix where he served as Vice President of Surgical Sales, North America.

About symphonX™
symphonX™ is the world’s first single-port surgery solution compatible with a standard 15mm laparoscopic trocar. Emulating conventional, multi-port laparoscopy makes symphonX™ easy to use and enables surgeons to perform procedural steps ergonomically, allowing for a comfortable and secure single-port approach. symphonX™ is poised to deliver on the promise of single-port surgery, including fewer port-site complications, less post-operative pain, faster recovery and exceptional cosmesis, elevating the standard of care in laparoscopy.

About Fortimedix Surgical
Fortimedix Surgical is a fast growing medical device company, aiming to challenge the status quo in minimally invasive surgery by creating novel devices that capture the claimed benefits of single-port surgery. The company is headquartered in Nuth, The Netherlands, and has a U.S. subsidiary in San Diego, CA. With a strong history as a global market leader in contract stent manufacturing, Fortimedix has been a trusted partner in the medical device industry for over 15 years. Fortimedix Surgical is committed to driving the evolution of minimally invasive surgery through smart innovation across surgical specialties to improve the quality of life of patients throughout the world.
For more information, please visit

Forward-Looking Statements
Certain statements herein include “forward-looking” statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “project” or “continue” or the negative thereof or other similar words. All forward-looking statements involve risks and uncertainties, including, but not limited to, the protection of intellectual property, changes to governmental regulation of medical devices, the introduction of new products into the marketplace by competitors, changes to the competitive environment, the acceptance of new products in the marketplace, conditions of the surgical industry and economic and political conditions globally. Actual results may differ materially from those contemplated or implied by the forward-looking statements. The forward-looking statements speak only as of the date of this release and Fortimedix Surgical assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.


Contact Data